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Background. Tacrolimus (Tac) and mycophenolate 
mofetil CMMF) are newly approved immunosuppres-
sive agents. However, the safety and efficacy of the 
combination of MMF and Tac in primary liver trans-
plantation has not been determined. 
Methods. An Institutional Review Board-approved, 
open-label prospective randomized protocol was initi-
ated to study the efficacy and toxicity of Tac and ste-
roids (double-drug therapy) versus Tac, steroids, and 
MMF (triple-drug therapy) in primary adult liver 
transplant recipients. Both groups of patients began 
on the same doses of Tac and steroids. Patients ran-
domized to triple-drug therapy also received 1 g of 
MMF twice a day. 
Results. Between August 1995 and January 1997,200 
patients were enrolled, 99 in double-drug therapy and 
101 in triple-drug therapy. All patients were followed 
until May 1997, with a mean follow-up of12.7 months. 
During the study period, 28 of 99 patients in double-
drug therapy received MMF to control ongoing acute 
rejection, nephrotoxicity, and/or neurotoxicity. On the 
other hand, 61 patients in triple-drug therapy discon-
tinued MMF for infection, myelosuppression, and/or 
gastrointestinal disturbances. By an "intention-to-
treat analysis." the actuarial I-year patient survival 
rate was 85.1% in double-drug therapy and 83.1% in 
triple-drug therapy (P=O.77). The actuarial I-year 
graft survival rate was 80.2% for double-drug therapy 
and 79.2% for triple-drug therapy (P=O.77). Forty-one 
patients (41.4%) in double-drug therapy and 32 (31.7%) 
in triple-drug therapy had at least one episode of re-
jection, but this was not statistically significant 
(P=O.15). The mean maintenance dose of corticoste-
roids was slightly lower in triple-drug compared with 
double-drug therapy. 
Conclusion. Patient and graft survival rates were 
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similar in both groups_ There was a trend to a lower 
incidence of rejection, reduced nephrotoxicity, and a 
lesser amount of maintenance corticosteroids in tri-
ple-drug therapy compared with double-drug therapy. 
Within the past two years, the Food and Drug Administra-
tion has approved two new immunosuppressive agents, de-
signed for chronic administration. Tacrolimus (Tac*) is a 
potent immunosuppressive agent, shown to significantly re-
duce episodes of acute rejection in primary liver transplant 
recipients when compared with cyclosporine (esA)-based im-
munosuppression (1-3). It was determined in early clinical 
transplant trials that the principal limitations of Tac are 
nephrotoxicity, neurotoxicity, and diabetogenicity (reviewed 
in 4). 
Prospective, randomized double-blinded clinical trials com-
paring esA, steroids, and mycophenolate mofetil (MMF) to 
esA, steroids, and placebo (or azathioprine) revealed signif-
icantly reduced episodes of rejection in kidney transplant 
patients who were randomized to MMF (5-6), The principal 
toxicities observed in these trials were bone marrow suppres-
sion and gastrointestinal toxicity. 
Not only do Tac and MMF have different toxicity profiles 
but also different modes of action (7. 8). The aim of the 
present study was to evaluate the combination of Tac and 
steroids to Tac. steroids, and ~Mc in primary adult liver 
transplant recipients in terms of patient and graft survival, 
incidence of rejection, and drug toxicity profiles. This repre-
sents a scheduled interim analysis after enrollment of 50% of 
the projected number of patients (e.g., 400 total) at a single 
center. , __ 
A prospective randomized trial protocol for adult (age 2: 18 
years) primary orthotopic liver transplantation (OLT) pa-
tients comparing Tac and steroids versus Tac, steroids, and 
MMF was approved by the Institutional Review Board in 
August 1995. Randomization was based on a sequential draw 
of assignments using a variable block randomization proce-
dure (9). All consenting adults with primary orthotopic liver 
transplants were enrolled in the study. 
Patients in both arms received Tac at 0.03 to 0.05 mglkg'l 
day intravenously as a starting dose. commencing immedi-
ately after reperfusion of the liver allograft. Subsequent ad-
justments in the Tac dosage were made to achieve a whole 
* Abbreviations: esA. cyclosporine: D. tacrolimus and steroids: 
double-drug therapy: MMF. mycophenolate mofetil; OLT, orthotopic 
liver transplantation: T. tacrolimus. steroids. and mycophenolate 
mofetil: triple-drug therapy: Tac. tacrolimus. 
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blood Tac concentration of 20 nglml when on intravenous 
therapy and a trough level of 15 nglml when on oral Tac 
therapy during the first postoperative month. The target 
trough levels were 12-15 nglml in the second postoperative 
month and 10-12 nglml in the third postoperative month. All 
patients also received 1 g of methylprednisolone on reperfu-
sion of the liver and a 6-day methylprednisolone taper, start-
ing at 200 mglday and ending at a baseline dose of 20 mglday. 
Subsequent adjustment in baseline prednisone was made 
depending on the clinical course of the patient. Patients who 
experienced an acute rejection episode were initially treated 
with a single 1-g bolus of methylprednisolone and optimiza-
tion ofTac levels. In the event that the liver function tests did 
not improve within 24 hr after the steroid bolus. a gradual 
steroid taper was introduced, starting at 200 mg of methyl-
prednisolone and tapering to 20 mg of prednisone over the 
ensuing 5 days. Patients who failed augmented steroids were 
considered as having steroid-resistant rejection and were 
treated With 5 mg of OK.T3 (Ortho Biotech, Raritan, NJ) for 
7-10 days. Patients who were randomized to Tac, steroids, 
and MMF (triple-drug therapy; T) received 1 g ofMMF twice 
a day from the day of transplant. Protocol allowed reduction 
or discontinuation of MMF if there were any side effects 
ascribed to MMF or if the clinical course of the patient 
deemed it necessary to do so. In addition, patients random-
ized to double-drug therapy could receive MMF to control 
acute rejection or Tac-related toxicity. Criteria used for the 
pathologic diagnosis of acute hepatic rejection were as de-
scribed in an international consensus document (10). 
Between August 1995 and January 1997, 200 patients 
were enrolled in the study. There were no significant differ-
ences in recipient age, sex, or United Network of Organ 
Sharing status at the time of transplant. The mean age was 
53.1=12 years in D and 52.8=12 years in T. The proportion 
of male/female was 58/41 in D versus 53/48 in T. Fourteen 
donors were above the age of 65 years in T compared with 11 
in D. For the purposes of this report. all patient statuses were 
updated to May 5, 1997. The mean follow-up was 12.7=0.4 
SE months (median 12.9; range 3.5 to 20.9). Patient and graft 
survival rates were calculated using the Kaplan-Meier 
method and compared by the log-rank test. Differences be-
tween means were tested by the standard two-sample t test, 
whereas differences in proportions were tested by the Pear-
son chi-square test. Analyses were performed by "intention-
to-treat" analysis. A P value less than 0.04, therefore, was 
considered statistically significant. Continuous data are pre-
sented as mean = SD, and categorical data are presented as 
proportions. 
The Kaplan-Meier actuarial patient and graft survival 
rates are shown in Figure 1. The I-year actuarial patient 
survival rate was 85.1% for D and 83.1'1: for T (P=0.77). 
Patients who died with a functioning graft were considered 
as graft loss. Fifteen (15.2%) patients in D and seventeen 
( 16.8%) patients in T died during the follow-up period. The 
main causes of deaths were sepsis and multisystem organ 
failure (9 in D. 8 in T). Other causes of deaths included 
intracranial bleeding (1 in D. 3 in T), pnmary graft nonfunc-
tion I 1 in D. 2 in Tl. cardiopulmonary I 1 in D, 2 in Tl, 
cryptococcus (1 in D, 1 in T), hemorrhagic gastritis (1 in D J, 
recurrent hepatitis C ( 1 in D I. and status epilepticus (1 in Tl. 
Seven patients in D and 11 patients in T required retrans-
plantation. The causes of retransplantation included: pri-
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FIGURE 1. Kaplan Meier actuarial survival curve for primary liver 
transplant patient and graft survival rates for tacrolimus and ste-
roids (double-drug; Dl therapy, vis tacrolimus, steroids, and MMF 
(triple-drug; T) therapy. 
mary nonfunction (4 in D and 8 in T; not significant); hepatic 
artery thrombosis (3 in Dl; and recurrence of hepatitis C viral 
infection resulting in liver failure (2 in T). One patient in 
T was retransplanted because of graft failure due to post-
transplant lymphoproliferative disease and graft-versus-host 
disease. The I-year actuarial graft survival rate was 80.2% 
for D and 79.2% for T (Fig. 1). 
In the follow-up period of 3.5 to 12 months, 41 (41.4%) 
patients in D and 32 (31.7%) patients in T had at least one 
episode of rejection. Eleven patients in D and 8 patients in 
T had more than one episode of rejection (Table 1). The total 
episodes of rejections were 57 in D and 44 in T. The median 
time to first episode of rejection was 16 days in D and 18 days 
in T. Freedom from rejection was observed in 58 patients 
(58.5%) in D and 69 (68.3'1:) in T (P=0.15). In D, 26 of 59 
(44%) episodes of rejection responded to 1 g of methylpred-
nisolone alone. whereas 27 of 59 (46%) required an additional 
steroid taper over the next 5 days. In four patients, OKT3 
was used to control steroid-resistant rejection. In T, 17 (43%) 
episodes of rejection responded to 1 g of methylprednisolone, 
TABLF...1-
Random Episodes of rejection Freedom from Rejection rejection. group 2 3 -I Total n(%) 
Early (n) Double 36 6 2 0 44 
<3 Mo Triple 24 2 0 27 
Late In) Double 5 5 2 13 
3-12 Mo Triple 8 6 2 17 
Total In) Double 41 11 4 57 58 (58.59C1 
Early - Late Triple 32 S 3 44 69 (68.3%) 
Treatment of episodes of 
rejectIOn 
SMG SM- RC OKT3 RC 
Double 26 28 0 -I 57 
Triple 17 22 :2 3 44 
a SM. 1 g of methylprednisolone: Re. 600 mg of methyprednisolone 
lor oral prednisone) over 5 days. 
c; 
.. 
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and 22 (50%) episodes required additional steroid taper over 
the next 5 days. Three of these episodes of rejection were 
treated with OKT3. No grafts in either group were lost due to 
rejection. 
The maintenance dose of Tac and the whole blood trough 
concentration of Tac in both groups of patients was similar. 
However. the mean maintenance baseline dose of prednisone 
per patient was slightly lower in the triple-drug therapy 
group compared with the double-drug therapy group. This 
was not statistically significant (Table 2). 
During the study period, 61 of the 101 patients who were 
randomized to T discontinued MMF for infection (n=23: sep-
sis 12; cytomegalovirus 7; recurrent hepatitis C virus 3; and 
cryptococcus 1), myelosuppression (n=20: leukopenia 12; 
anemia 7; and thrombocytopenia 1), gastrointestinal distur-
bances (n= 14: diarrhea 10; nausea/vomiting 2; anorexial-
prolonged ileus 1), and other miscellaneous reasons (n=4). 
Mean time to discontinue MMF was 64:1:82 days. During the 
same time, 28 of 99 patients who were randomized to D 
required the addition of MMF for ongoing acute rejection 
(16), nephrotoxicity (6), nephrotoxicity with rejection (3), 
neurotoxicity (2), neurotoxicity, and nephrotoxicity and re-
jection (1). The mean interval from OLT to the addition of 
MMF was 53:::80 days. 
The rate of positive blood cultures was 40 (40.4%) in D 
versus 41 (40.6%) in T. Cytomegalovirus infection was 16.2% 
in D versus 17.8% in T. The rate of fungal infection was 
10.1% in D versus 5% in T. 
Before OLT, five patients who were subsequently random-
ized to T were on dialysis as compared with two in D. After 
OLT, 21 (all new onset) patients required dialysis in D, and 
19 (14 new onset) required dialysis in T (P=0.188). The 
majority of patients with renal failure (either pre- or pos-
tOLT) improved; only one patient in D and two patients in 
T remain on dialysis (one of the patients in T was trans-
planted for hyperoxalosis and is awaiting kidney transplan-
tation). The pre- and postOLT mean serum creatinine levels 
and blood urea nitrogen levels are shown in Table 2. Al-
though the serum creatinine level was lower in the triple-
drug therapy group during the first month compared with 
the double-drug therapy group (Table 2), this difference did 
not reach statistical significance (P=O.071. 
A considerable number of patients were anemic (hemato-
crit <25%; 12% in D an~ "t3% in T), leukopenic (leukocyte 
count <4.000/mm3 ; 24% in D and 31% in T), and/or thr~m­
bocytopenic (platelet count <50,OOO/mm3 ; 24% in D and 25% 
in T) before OLT. Most often these hematologic parameters 
were ascribed to hypersplenism. The percentage of patients 
with anemia. leukopenia, and/or thrombocytopenia before 
OLT and at various times after OLT is shown in Table 2 for 
both groups of patients. 
Diarrhea was the most common gastrointestinal symptom 
observed in both groups of patients. surprisingly with equal 
proportions in both groups. Twenty-five patients in T and 24 
patients in D experienced diarrhea in the postoperative pe-
riod; only four of these patients in D experienced diarrhea 
after the addition of MMF for rejection. In T, 19 patients had . 
diarrhea when they were on MMF, and the remaining 6 
patients were not on MMF. In T. two patients were reported 
to have nausea and vomiting, one patient had anorexia. and 
one other patient experienced prolonged paralytic ileus. 
A number of trials using MMF have been conducted in 
renal transplantation using CsA-based immunosuppression 
(6-8). This is the first report on a large randomized clinical 
trial of MMF with Tac in OLT patients. Although the prin-
ciple of immunosuppressive therapies in liver and kidney 
transplantation is similar, the nature of liver transplant 
patients and the complexity of their postoperative manage-
ment often dictates practical changes. For example, a signif-
icant number of patients with end-stage liver disease have 
portal hypertension and splenomegaly at the time of OLT, 
resulting in hypersplenism leading to thrombocytopenia, leu-
kopenia. and anemia. The use of myelosuppressive agents. 
such as azathioprine. has historically been associated with 
TABLE 2. 
Treatment PostL Tx days Mean Pre-LTx" group i 14 27 28 60 90 180 270 ;]60 
Renal function 
BUN Imgldl) Double 21 52 56 51 45 29 28 29 26 23 
Triple 22 45 45 49 44 -~ 24 27 26 23 
Creatmine I mg/dlJ Double 1.26 1.77 2 2.1 2.1 1.41 L37 1.37 1.47 1.39 
Triple 1.32 1.55 1.6 1.8 1.6 1.44 L31 1.38 1..16 1.42 
Hematology 
Anemia"" IHct<25%) Double 12 14 25 19 22 9 4 4 0 :3 
Triple 13 12 15 20 22 -; 6 2 2 0 
Leukopenia '" IWBC<4.000/mm:) Double 24 0 6 0 4 17 15 22 14 22 
Triple 31 4 3 9 9 20 KI~ _I 20 22 20 
Thrombocytopenia roc I platelets< 50.000/mn' Double 24 20 12 :3 :2 ., 4 :2 0 :3 
Triple 25 25 5 4 6 :3 :3 2 2 .'l 
Baseline immunosuppression 
Tacrolimus dose I mg/day) Double 8..1 9.5 10.5 9.9 .'l.6 ~KO - .J 1.- 5.7 5.:3 
Triple 9.2 10.8 9.6 9.2 H 8 6.9 6.5 53 
Tacrolimus level I ng/mlJ Double 15.8 14.5 15.3 14.5 11.9 12.2 11.1 10.1 10.6 
Triple 15.1 14.2 13.9 14.:.! 1l.S 11.6 11.5 10.6 10.:-
Prednisone I mwday J Double 20 18.6 16.1 14.2 10 18.7 5.7 4.6 3.3 
Triple 20 18.3 15.6 13.2 9.1 7.2 :>.3 3.6 2 
, .\bbreviatlOn used in table: LTx. liver transplantation. 
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further bone marrow suppression, leading to greater risk of 
postOLT infection (1). Similar concerns are apparent when 
using MMF, which can potentially depress bone marrow. 
Reduction in immunosuppression is a mainstay in address-
ing life-threatening infections (12). Sixty percent of the pa-
tients randomized to T discontinued the :.1MF for adverse 
events related to postOLT infection, suppressed formed blood 
elements, and gastrointestinal disturbances. MMF could 
have been continued in the presence of infection. however, in 
the absence of rejection and normal liver function it was felt 
that three antirejection medications are not necessary. The 
interim analysis has highlighted that many of these side 
effects were also seen in the D group. 
Despite the concerns with the addition of a new immuno-
suppressive agent (MMF) in combination with another po-
tent immunosuppressive agent (Tac), there was a trend to a 
lower rejection rate in T. In addition, the maintenance and 
cumulative doses of steroids were lower in T. Despite similar 
doses of Tac and trough concentrations of Tac, renal function 
seemed to be better preserved in T. Patient survival and graft 
survival were similar in both groups of patients, although 
there were more retransplants in T, mainly because of more 
marginal donors rather than because of the effect of MMF. 
This interim report, comparing Tac and steroids versus 
Tac, steroids, and MMF has shown similar patient and graft 
survival rates in both groups. The rates of postoperative 
infection, pre- and postoperative hematological side effects, 
and gastrointestinal side effects were similar in both groups 
of patients. However, their presence posed an additional 
clinical management problem and led to discontinuation of 
MMF in nearly 60% of the patients in the triple-drug therapy 
group. There was a trend of a lower rate of rejection, im-
proved renal function, and lower use of steroids in triple-drug 
therapy as compared with double-drug therapy. However, 
none of these parameters reached a statistical significance. 
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